Health Care · Biological Products, (No Diagnostic Substances)

BIIB Biogen SEC Filings & Insider Trading Activity 2026

company
CIK 875045115 filings
S&P 500

BIIB at a glance

Biogen (BIIB, SEC CIK 875045) filed its latest 10-K annual report on February 6, 2026, a 10-Q quarterly report on October 28, 2026, an 8-K current report on October 28, 2026 and Form 4 insider filings as recently as November 2, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Biogen (BIIB) reported revenue of $9.9 billion (up 2.2% from FY2024) and net income of $1.3 billion. Diluted EPS was $8.79.
  • As of September 30, 2026, 43 institutional investment managers tracked by SignalX reported holding Biogen (BIIB) shares worth $13.0 billion in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Minor Lloyd on August 4, 2026 of 593 shares at $200.96 per share.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$9.9B
+2.2% vs prior year
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
43 funds
$13.0B · +0 vs prior quarter
Latest 8-K
Oct 28, 2026
Item 2.02

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business model: Global biopharmaceutical company developing and commercializing therapies primarily for neurology, specialized immunology, and rare diseases
  • New or emphasized segment: Expanded collaboration with Genentech on multiple anti-CD20 therapies including recently approved GAZYVA for lupus nephritis in Oct 2025
  • Strategic shift: Increased focus on biosimilars portfolio commercialization, including BENEPALI, IMRALDI, and FLIXABI as key growth drivers
  • Quantitative highlight: Acquired in-process research and development expense surged to $471.8M in 2025 from $61.5M in 2024, signaling aggressive pipeline investment
  • Noteworthy fact: Completed agreement to acquire Reata Pharmaceuticals (2023 filing) reflected in continued integration and intangible assets balancing $9.18B as of Dec 2025

Risk Factors

  • Regulatory risk: IRA Medicare Part D redesign caused $90 million 2025 revenue loss, impacting SKYCLARYS and MS portfolio with future pricing enforcement uncertainty
  • Geopolitical risk: Russia-Ukraine conflict may disrupt supply; revenues from Russia, Ukraine, Middle East each <2.0% of total revenue in 2023-2025
  • Supply chain risk: TECFIDERA, VUMERITY, LEQEMBI raw materials and components partly sourced outside U.S., with tariffs and supplier substitution risks
  • Competitive risk: TECFIDERA patent revoked by European Patent Office Nov 2025; multiple generic entrants causing significant revenue erosion
  • Financial risk: $1.75 billion 2025 Senior Notes issuance with proceeds used to redeem $4.050% notes; $4.2 billion cash and equivalents end 2025

Management Discussion & Analysis

  • No profitability or margin figures mentioned
  • Capital investments include new biologics manufacturing facility in Solothurn, Switzerland; expansion supports LEQEMBI and TYSABRI production
  • Future growth dependent on new product development, regulatory approvals, patent protection, and external business opportunities

AI summary of the BIIB 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • Newly added international-trade risk: Section 232 Proclamation imposed 100% tariffs on certain pharmaceutical imports beginning July 31, 2026
  • Most material product risk: TECFIDERA revenue fell 50.3% to $282.4 million after European patent revocation and generic entry
  • Regulatory pricing risk: OBBBA implementation guidance remains pending, with most provisions effective in 2027 and 2028
  • Operational risk: Apellis integration may delay expected benefits from EMPAVELI and SYFOVRE commercialization
  • Financial risk: Cash and marketable securities declined to $1.3 billion while borrowings increased to $7.7 billion following Apellis acquisition

Management Discussion & Analysis

  • Revenue $2,804.1M, up from $2,534.7M YoY, with product revenue $2,088.7M vs $1,846.9M
  • Net loss $(20.6)M vs $466.5M income YoY, with net margin (0.7)% vs 18.4%
  • Best product line SPINRAZA, $460.6M vs $374.0M; worst TECFIDERA, $82.0M vs $168.2M
  • Operating cash flow $1,735.2M for nine months vs $1,692.7M; cash $1,303.9M vs $3,008.5M
  • Apellis acquisition deployment $5,071.1M, with $2.0B term loan financing and $400.0M revolving-facility drawdown

AI summary of the BIIB 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Oct 28, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Q3 revenue $2.8B, up 11% year over year, signaling renewed growth led by the Growth Portfolio and Apellis products
  • Growth Portfolio revenue $1.26B, up 49%, now 63% of Core Pharmaceutical revenue

Item 2.02: Results of Operations and Financial Condition

  • Biogen reported third-quarter fiscal 2026 results for the period ended September 30, 2026
  • Full financial results and management commentary are contained in Exhibit 99.1, the accompanying press release
Filed Jul 29, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q2 2026 results for the quarter ended June 30, 2026 announced by Biogen
  • Detailed financial results and operating metrics available in Exhibit 99.1 press release

Item EX-99.1: Item EX-99.1

  • Q2 revenue $2.736B, up 3% YoY, led by Growth Portfolio revenue of $1.06B, up 24%
  • Non-GAAP EPS $3.60 versus $5.47, pressured by acquisition costs, pipeline investment, and Apellis financing expense
Filed Jul 1, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q2 2026 GAAP and non-GAAP EPS expected to include approximately $164 million of pre-tax milestone-related expense
  • Q2 EPS impact estimated at approximately $0.95 per diluted share

AI summaries of BIIB 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for BIIB

Don't miss the next BIIB filing

  • Alerts as it files. A push when BIIB files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut BIIB, by share count.
  • Ask anything. An AI agent that reads every BIIB filing and answers with sources.

BIIB alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Grogan JaneFOct 30, 2026$253.62
Grogan JaneMOct 30, 2026-
Grogan JaneMOct 30, 2026-
Godbout SeanMOct 2, 2026-
Godbout SeanFOct 2, 2026$219.88
Godbout SeanMOct 2, 2026-
Godbout SeanAOct 1, 2026-
Parini MichaelASep 1, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue$9.8B$9.7B$9.9B
Net Income$1.2B$1.6B$1.3B
Net Margin11.8%16.9%13.1%
Balance Sheet
Total Assets$26.8B$28.0B$29.4B
Equity$14.8B$16.7B$18.3B
ROE7.8%9.8%7.1%
Per Share
EPS$7.97$11.18$8.79
Cash Flow
Operating CF$1.5B$2.9B$2.2B
CapEx-$153.7M$153.8M

Source: XBRL data in Biogen (BIIB)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate BIIB share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
BIIB shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202643$13.05B
Q2 202643$16.09B
Q1 202640$12.48B
Q4 202539$11.75B
Q3 202541$8.65B
Q2 202538$7.43B
Q1 202537$6.15B
Q4 202436$5.77B
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 317 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

BIIB filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 2, 2026--
10-QOct 28, 2026Analysis
8-KOct 28, 2026Analysis-
4Oct 5, 2026--
4Sep 3, 2026--
4Aug 5, 2026--
8-KJul 29, 2026Analysis-
10-QJul 29, 2026Analysis
8-KJul 1, 2026Analysis-
4Jun 11, 2026--
4Jun 11, 2026--
4Jun 11, 2026--
4Jun 11, 2026--
4Jun 11, 2026--
4Jun 11, 2026--
4Jun 11, 2026--
4Jun 11, 2026--
4Jun 11, 2026--
8-KJun 10, 2026-
8-KJun 10, 2026Analysis
8-KMay 14, 2026Analysis
4May 5, 2026--
10-QApr 29, 2026Analysis
8-KApr 29, 2026Analysis-
SC 13GApr 29, 2026-

Related Health Care companies

All Health Care →

BIIB SEC filings: frequently asked questions

Which institutions hold BIIB stock?

As of September 30, 2026, the largest Biogen (BIIB) holders among the 13F filers tracked by SignalX were BlackRock ($3.6 billion), Vanguard Capital Management LLC ($2.2 billion), State Street Corp ($1.7 billion), Vanguard Portfolio Management LLC ($1.5 billion), Morgan Stanley ($566.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was BIIB's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Biogen (BIIB) reported revenue of $9.9 billion (up 2.2% from FY2024) and net income of $1.3 billion. Diluted EPS was $8.79. The figures come from the XBRL data in the 10-K.

What are the main risks in BIIB's latest 10-K?

In the 10-K filed February 6, 2026, Biogen (BIIB) flagged: Regulatory risk: IRA Medicare Part D redesign caused $90 million 2025 revenue loss, impacting SKYCLARYS and MS portfolio with future pricing enforcement uncertainty. Geopolitical risk: Russia-Ukraine conflict may disrupt supply; revenues from Russia, Ukraine, Middle East each <2.0% of total revenue in 2023-2025. (AI summary of the Risk Factors section.)

What did BIIB report in its latest 8-K?

Biogen (BIIB) filed an 8-K on October 28, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 revenue $2.8B, up 11% year over year, signaling renewed growth led by the Growth Portfolio and Apellis products.

What are the latest BIIB SEC filings?

Biogen (BIIB) filed its latest 10-K annual report on February 6, 2026, a 10-Q quarterly report on October 28, 2026, an 8-K current report on October 28, 2026 and a Form 4 insider filing on November 2, 2026.

What is BIIB's SEC CIK number?

Biogen (BIIB)'s SEC Central Index Key (CIK) is 875045. EDGAR lists every BIIB filing under that number.

Ask anything about BIIB

The research agent reads BIIB's filings, financials, insider trades and 13F holders, then answers with sources.